Literature DB >> 19181544

Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells.

Wei Qu1, Yin-Dong Kang, Mei-Sheng Zhou, Li-Li Fu, Zhen-Hao Hua, Li-Ming Wang.   

Abstract

OBJECTIVE: To investigate the inhibitory effect of histone deacetylase (HDAC) inhibitors (MS-275 and TSA) on T24 human bladder cancer cells in vitro, and explore the possible mechanism.
METHODS: The MTT assay was employed to evaluate the inhibitory effect of MS-275 and TSA on T24 cell growth. FCM was used to analyze the variation of T24 cell cycle distribution and the apoptotic ratio after T24 cells were treated with MS-275 and TSA. Histone acetylation level was detected by Western blot. mRNA expression of p21 WAF1/CIP1, cyclin A, and cyclin E was measured by FQ-PCR. Dynamic changes of Bcl-2 and bax expression were detected by FCM.
RESULTS: MS-275 and TSA inhibited T24 cell growth in a concentration and time-dependent manner. Treatment with 4 μmol/l MS-275 or 0.4 μmol/l TSA blocked cell cycling in the G0/G1 phase and induced a significant increase in cell apoptosis. MS-275 and TSA significantly increased the level of histone acetylation, induced p21CIP1WAF1 mRNA expression, and inhibited cyclin A mRNA expression, though no significant effect was observed on cyclin E. Bcl-2 expression was down-regulated, while bax expression was up-regulated.
CONCLUSION: HDAC inhibitors can block bladder cancer cell cycle in vitro and induce apoptosis. The molecular mechanism may be associated with increased level of histone acetylation, down-regulation of p21WAF1/CIP1 expression, up-regulation of cyclin A expression, and dynamic change of bcl-2 and bax expression.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19181544     DOI: 10.1016/j.urolonc.2008.11.018

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  15 in total

1.  Histone Deacetylase Inhibitor M344 Inhibits Cell Proliferation and Induces Apoptosis in Human THP-1 Leukemia Cells.

Authors:  Xiaohua Li; Ben D Chen
Journal:  Am J Biomed Sci       Date:  2009-06-09

2.  Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.

Authors:  Marion Ganslmayer; Annette Zimmermann; Steffen Zopf; Christoph Herold
Journal:  World J Gastroenterol       Date:  2011-08-21       Impact factor: 5.742

Review 3.  Histone deacetylases and mechanisms of regulation of gene expression.

Authors:  Hong Ping Chen; Yu Tina Zhao; Ting C Zhao
Journal:  Crit Rev Oncog       Date:  2015

4.  PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma.

Authors:  Giselle Saulnier Sholler; Erika A Currier; Akshita Dutta; Marni A Slavik; Sharon A Illenye; Maria Cecilia F Mendonca; Julie Dragon; Stephen S Roberts; Jeffrey P Bond
Journal:  J Cancer Ther Res       Date:  2013-12-28

5.  [Signal transduction in urothelial cancer: how exactly do we know the targets for targeted therapy?].

Authors:  G Niegisch; A Koch; J Knievel; W A Schulz; P Albers
Journal:  Urologe A       Date:  2010-11       Impact factor: 0.639

6.  Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.

Authors:  Wei-Chou Lin; Fu-Shun Hsu; Kuan-Lin Kuo; Shing-Hwa Liu; Chia-Tung Shun; Chung-Sheng Shi; Hong-Chiang Chang; Yu-Chieh Tsai; Ming-Chieh Lin; June-Tai Wu; Yu Kuo; Po-Ming Chow; Shih-Ming Liao; Shao-Ping Yang; Jo-Yu Hong; Kuo-How Huang
Journal:  J Mol Med (Berl)       Date:  2018-10-04       Impact factor: 4.599

7.  The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines.

Authors:  Jacob J Elmer; Matthew D Christensen; Sutapa Barua; Jennifer Lehrman; Karmella A Haynes; Kaushal Rege
Journal:  Biotechnol Bioeng       Date:  2015-12-30       Impact factor: 4.530

Review 8.  Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.

Authors:  Jiahuai Tan; Shundong Cang; Yuehua Ma; Richard L Petrillo; Delong Liu
Journal:  J Hematol Oncol       Date:  2010-02-04       Impact factor: 17.388

9.  SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection.

Authors:  Xin Zhang; Shu Han; Yindong Kang; Meng Guo; Shanjuan Hong; Fang Liu; Shangxi Fu; Liming Wang; Quan-Xing Wang
Journal:  Cell Mol Immunol       Date:  2012-08-27       Impact factor: 11.530

10.  Molecular Characterization and Clinical Relevance of Lysine Acetylation Regulators in Urological Cancers.

Authors:  Jian Zhang; Chunning Zhang; Huali Jiang; Hualong Jiang; Yawei Yuan
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.